Evaluation of topical econazole nitrate formulations with potential for treating Raynaud’s phenomenon

References

• Allen LV Jr. 2017. Progesterone 50 mg/g in VersaBase Cream. US Pharm. 42:47–48.
   Google Scholar
• Baumhäkel M, Böhm M. 2010. Recent achievements in the management of Raynaud's phenomenon. Vasc Health Risk Manag. 6:207.
   PubMedGoogle Scholar
• Böhling A, Bielfeldt S, Himmelmann A, Keskin M, Wilhelm KP. 2014. Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy. Skin Res Technol. 20:50–57.
   PubMed Web of Science ®Google Scholar
• Bousmina M. 1999. Rheology of polymer blends: linear model for viscoelastic emulsions. Rheologica Acta. 38:73–83.
   Web of Science ®Google Scholar
• Brodin B, Steffansen B, Nielsen CU. 2010. Passive diffusion of drug substances: the concepts of flux and permeability. In: Steffansen B, Brodin B, Nielsen CU, editors. Molecular biopharmaceutics: aspects of drug characterisation, drug delivery and dosage form evaluation. London: Pharmaceutical Press; p. 135–151.
   Google Scholar
• Brown KM, Middaugh SJ, Haythornthwaite JA, Bielory L. 2001. The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study. J Behav Med. 24:137–153.
   PubMed Web of Science ®Google Scholar
• Carvalho FC, Barbi MS, Sarmento VHV, Chiavacci LA, Netto FM, Gremiao MP. 2010. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. J Pharm Pharmacol. 62:430–439.
   PubMed Web of Science ®Google Scholar
• Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW. 2009. MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 60:870–877.
   PubMed Web of Science ®Google Scholar
• Coppock JS, Hardman J, Bacon P, Woods K, Kendall M. 1986. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud’s phenomenon. Postgrad Med J. 62:15–18.
   PubMed Web of Science ®Google Scholar
• Dantas MGB, Reis SAGB, Damasceno CMD, Rolim LA, Rolim-Neto PJ, Carvalho FO, Quintans-Junior LJ, Almeida JRGdS. 2016. Development and evaluation of stability of a gel formulation containing the monoterpene borneol. ScientificWorldJournal. 2016:1.
   Google Scholar
• Dick IP, Scott RC. 1992. Pig ear skin as an in-vitro model for human skin permeability. J Pharm Pharmacol. 44:640–645.
   PubMed Web of Science ®Google Scholar
• Djalil A, Ambarwati T, Genatrika E. 2018. Characterization of sunscreen cream containing benzophenone-3,3’,4,4’-tetracarboxylate dianhydride. Iop Conf Ser Mater Sci Eng. 434:012090.
   Google Scholar
• Firooz A, Nafisi S, Maibach HI. 2015. Novel drug delivery strategies for improving econazole antifungal action. Int J Pharm. 495:599–607.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT. 1998. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med. 129:208–211.
   PubMed Web of Science ®Google Scholar
• Fraenkel L. 2002. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep. 4:123–128.
   PubMedGoogle Scholar
• Franks A. 1982. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. The Lancet. 319:76–77.
   Google Scholar
• Gajra B, Pandya SS, Singh S, Rabari HA. 2014. Mucoadhesive hydrogel films of econazole nitrate: formulation and optimization using factorial design. J Drug Deliv. 2014:1.
   Google Scholar
• Ge S, Lin Y, Lu H, Li Q, He J, Chen B, Wu C, Xu Y. 2014. Percutaneous delivery of econazole using microemulsion as vehicle: formulation, evaluation and vesicle-skin interaction. Int J Pharm. 465:120–131.
   PubMed Web of Science ®Google Scholar
• Goto N, Morita Y, Terada K. 2016. Deposits from creams containing 20%(w/w) urea and suppression of crystallization (part 1): rate of crystallization from cream containing 20% (w/w) urea and evaluation of the properties of the deposit. Chem Pharm Bull. 64:1084–1091.
   PubMed Web of Science ®Google Scholar
• Hadgraft J, Lane ME. 2005. Skin permeation: the years of enlightenment. Int J Pharm. 305:2–12.
   PubMed Web of Science ®Google Scholar
• Heel R, Brogden R, Speight T, Avery G. 1978. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 16:177–201.
   PubMed Web of Science ®Google Scholar
• Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. 2007. Ibuprofen transport into and through skin from topical formulations: in vitro–in vivo comparison. J Investig Dermatol. 127:135–142.
   PubMed Web of Science ®Google Scholar
• Herrick AL. 2012. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 8:469–479.
   PubMed Web of Science ®Google Scholar
• Jones DS. 2016. Pharmaceutical disperse systems 3: ointments, pastes, lotions, gels and related formulations. In: Jones DS, editor. FASTtrack pharmaceutics dosage form and design. London: Pharmaceutical Press; p. 75–99.
   Google Scholar
• Jorge LL, Feres CC, Teles VE. 2011. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res. 4:11.
   Google Scholar
• Jug M, Mennini N, Kövér KE, Mura P. 2014. Comparative analysis of binary and ternary cyclodextrin complexes with econazole nitrate in solution and in solid state. J Pharm Biomed Anal. 91:81–91.
   PubMed Web of Science ®Google Scholar
• Kahaleh B, Altorok N, Boddu SHS, Nagaraja V, inventors. 2017 Mar 16. Treatment of Raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (trpm-8). United States patent US WO2017044458A1.
   Google Scholar
• Kesarpu S. 2015. Evaluation of drug release & anti-fungal activity of econazole nitrate from dermatological bases using reduced level of the drug. The Brooklyn Center: Long Island University.
   Google Scholar
• Kranz G, Schaefer H, Zesch A. 1977. Hydrocortisone (cortisol) concentration and penetration gradient. Acta Dermato-Venereologica. 57:269–273.
   PubMed Web of Science ®Google Scholar
• Lambers H, Piessens S, Bloem A, Pronk H, Finkel P. 2006. Natural skin surface pH is on average below 5, which is beneficial for its resident flora. Int J Cosmet Sci. 28:359–370.
   PubMedGoogle Scholar
• LeRoy EC. 1996. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am. 22:675–694.
   PubMed Web of Science ®Google Scholar
• Levien TL. 2010. Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag. 6:167.
   PubMedGoogle Scholar
• Lewis T. 1929. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers: a variety of Raynaud's disease. Heart. 15:7–101.
   Google Scholar
• Mohamed AI, Abd-Motagaly AME, Ahmed OA, Amin S, Mohamed Ali AI. 2017. Investigation of drug–polymer compatibility using chemometric-assisted UV-spectrophotometry. Pharmaceutics. 9:7.
   Web of Science ®Google Scholar
• Nishimoto Y, Kaneki Y. 2003. Detection of water–polar solvent interaction using melting of a eutectic. Thermochim Acta. 399:139–144.
   Web of Science ®Google Scholar
• OECD. 2004a. Test Guideline 427: Skin absorption: in vivo Method. Paris: Organisation for Economic Co-operation and Development.
   Google Scholar
• OECD. 2004b. Test Guideline 428: Skin absorption: in vitro Method. Paris: Organisation for Economic Co-operation and Development.
   Google Scholar
• OECD. 2004c. Guidance document for the conduct of skin absorption studies. OECD Series on Testing and Assessment Number 28. Paris: Organisation for Economic Co-operation and Development.
   Google Scholar
• Patel P, Bhadra S. 2015. Development of topical formulation of linezolid for complicated skin infections. Pharmagene. 2.
   Google Scholar
• Prausnitz MR, Elias PM, Franz TJ, Schmuth M, Tsai JC, Menon GK, Holleran WM, Feingold KR. 2012. Skin barrier and transdermal drug delivery. Dermatology. 3:2065–2073.
   Google Scholar
• Rezaeifar M, Mahmoudvand H, Amiria M. 2016. Formulation and evaluation of diphenhydramine gel using different gelling agents. Der Pharma Chemica. 8:243–249.
   Google Scholar
• Sabale V, Kunjwani H, Sabale P. 2011. Formulation and in vitro evaluation of the topical antiageing preparation of the fruit of Benincasa hispida. J Ayurveda Integr Med. 2:124.
   PubMedGoogle Scholar
• Schaefer H, Stüttgen G. 1976. Absolute concentrations of an antimycotic agent, econazole, in the human skin after local application. Arzneimittel-Forschung. 26:432–435.
   PubMed Web of Science ®Google Scholar
• Sheikh K, Saringat B, Bukhari N. 2011. Investigation of factors affecting physicochemical properties of palm-olein creams using optimisation techique-qualiy by design. J App Pharm. 3:301–319.
   Google Scholar
• Singh S, Parhi R, Garg A. 2011. Formulation of topical bioadhesive gel of aceclofenac using 3-level factorial design. Iran J Pharm Res. 10:435.
   PubMed Web of Science ®Google Scholar
• So J, Ahn J, Lee T-H, Park K-H, Paik M-K, Jeong M, Cho M-H, Jeong S-H. 2014. Comparison of international guidelines of dermal absorption tests used in pesticides exposure assessment for operators. Toxicol Res. 30:251.
   PubMedGoogle Scholar
• Sunderkötter C, Riemekasten G. 2006. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology. 45:iii33–iii35.
   PubMed Web of Science ®Google Scholar
• Teh L, Manning J, Moore T, Tully M, O'Reilly D, Jayson M. 1995. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Rheumatology. 34:636–641.
   Web of Science ®Google Scholar
• Trimble JO, inventor; Humco Holding Group, Inc., assignee. 2017 Sep 5. Transdermal silicone gel (silogel) compositions and methods of preparation. United States patent US US9750689B2.
   Google Scholar
• Wigley FM. 2002. Clinical practice. Raynaud's Phenomenon. N Engl J Med. 347:1001–1008.
   PubMed Web of Science ®Google Scholar